Back to 
Federated Hermes, Inc.
Federated Hermes, Inc.
ACRS
Showing 5 of 14 quarters
Position history for Federated Hermes, Inc.'s holdings in Aclaris Therapeutics, Inc.
No. Federated Hermes exited its ACRS (Aclaris Therapeutics) position in Q3 2025. Its Q2 2025 13F listed 902 shares worth $1,281. Federated Hermes first reported ACRS in Q1 2020 and held it in 12 quarterly 13F filings.
Final Value
$0
Final Shares
0
Total Value Change
-$15,868
Total Shares Change
-13,798
Quarter-by-Quarter History